Last updated July 18, 2026
Key finding
Least square mean difference of -0.73% (95% CI, -1.11 to -0.35; P =0.0002)
This study evaluated the efficacy and safety of HD-6277, a GPR40 agonist, in adults with Type 2 diabetes, finding significant reductions in HbA1c and fasting plasma glucose.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of HD-6277, a GPR40 agonist, in adults with Type 2 diabetes, finding significant reductions in HbA1c and fasting plasma glucose.
These findings suggest that HD-6277 could be a promising new treatment option for adults with Type 2 diabetes, potentially improving glycemic control and reducing the risk of diabetes-related complications. Effective management of blood sugar levels is crucial for preventing long-term health issues associated with diabetes.
The study's sample size and demographic diversity were not specified. Long-term effects and safety of HD-6277 were not assessed. Results may not be generalizable to all populations with Type 2 diabetes.
Published in
Publication details and source links for this paper.
Yong-ho L, Kyung WM, Jun HH, et al. Efficacy and Safety of HD-6277, a Novel GPR40 Agonist, in Adults with Type 2 Diabetes. Diabetes & Metabolism Journal. 2026;50(3):576-586. doi:10.4093/dmj.2025.0528
HD-6277 50 mg reduced HbA1c by -0.73% compared to placebo (P = 0.0002).
HD-6277 100 mg reduced HbA1c by -0.85% compared to placebo (P < 0.0001).
HD-6277 50 mg reduced fasting plasma glucose by -22.6 mg/dL (P = 0.0042).
HD-6277 100 mg reduced fasting plasma glucose by -27.7 mg/dL (P = 0.0002).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to HD-6277 50 mg, Resmetirom (100 mg) and Fasting Plasma Glucose (FPG), HbA1c, Change in insulinogenic index from baseline to week 12.
This study contributes evidence to
Primary intervention
HD-6277 50 mg
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
5
Evidence pairs
555
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
HD-6277 50 mg → Fasting Plasma Glucose (FPG)
HD-6277 50 mg → Fasting Plasma Glucose (FPG)
Resmetirom (100 mg) → Change in insulinogenic index from baseline to week 12
Resmetirom (100 mg) → Change in insulinogenic index from baseline to week 12
Resmetirom (100 mg) → Fasting Plasma Glucose (FPG)
Resmetirom (100 mg) → Fasting Plasma Glucose (FPG)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on HD-6277 50 mg and Fasting Glucose, HD-6277 50 mg and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on HD-6277 50 mg
Contributes to HD-6277 50 mg evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
HD-6277 50 mg appears to improve Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
HD-6277 50 mg appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Resmetirom (100 mg) appears to improve Change in insulinogenic index from baseline to week 12.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in insulinogenic index from baseline to week 12
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Resmetirom (100 mg) appears to improve Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
